Table 2 Gene alteration status (patients, N = 35)
KRAS mutation | |
 Mutation | 10 (28.6%) |
 Wild type | 18 (51.4%) |
 N/A | 7 (20.0%) |
NRAS mutation | |
 Mutation | 2 (5.7%) |
 Wild type | 17 (48.6%) |
 N/A | 16 (45.7%) |
BRAF mutation | |
 Mutation | 3 (8.6%) |
 Wild type | 27 (77.1%) |
 N/A | 5 (14.3%) |
HER2 overexpression | |
 Positive | 0 (0%) |
 Negative | 10 (28.6%) |
 N/A | 25 (71.4%) |
MSI (microsatellite instability) | |
 MSI-high | 0 (0%) |
 MSI-low | 21 (60.0%) |
 MSS (microsatellite stable) | 0 (0%) |
 N/A | 14 (40.0%) |
UGT1A1 | |
 TA6/TA6 | 13 (37.1%) |
 TA6/TA7 | 4 (11.4%) |
 TA7/TA7 | 1 (2.9%) |
 N/A | 17 (48.6%) |